The U.S. Food and Drug Administration (FDA) announced on Thursday its approval of Cobenfy (xanomeline and trospium chloride), a new medication developed by Bristol-Myers Squibb, for the treatment of adults with schizophrenia. Following the announcement, shares of Bristol-Myers Squibb increased approximately 5% in trading.
Latest articles
Latest News
What is NPR’s voting correspondent focusing on before Election Day?
With one month remaining until Election Day and early voting already in progress, NPR...
News
Get a MacBook Air for Half the Price of a Pro: Prime Day Deal
Amazon's Prime Day is once again providing an excellent opportunity for technology enthusiasts to...
Business
Trump and Musk Return to Site of Assassination Attempt
In a significant return to political campaigning, former President Donald Trump addressed supporters in...
Finance News
Dow and Oil Surge on Wall Street
Stocks witnessed a rally over the week following a robust jobs report, while oil...
More like this
Latest News
What is NPR’s voting correspondent focusing on before Election Day?
With one month remaining until Election Day and early voting already in progress, NPR...
News
Get a MacBook Air for Half the Price of a Pro: Prime Day Deal
Amazon's Prime Day is once again providing an excellent opportunity for technology enthusiasts to...
Business
Trump and Musk Return to Site of Assassination Attempt
In a significant return to political campaigning, former President Donald Trump addressed supporters in...